Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 9/20 | 0.46 |
| ▸ | TNK2 | Q07912 | 8/20 | 0.44 |
| ▸ | TTK | P33981 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | CDK4 | P11802 | 1/20 | 0.40 |
| ▸ | CCND1 | P24385 | 1/20 | 0.40 |
| ▸ | CCND2 | P30279 | 1/20 | 0.40 |
| ▸ | CCND3 | P30281 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8512662 | 0.93 | EGFR (0.45) | EGFRTNK2TTKKCNH2CDK4 | |
| SCHEMBL187898 | 0.91 | TNK2 (0.48) | EGFRTNK2TTK | |
| SCHEMBL8512740 | 0.86 | TNK2 (0.41) | EGFRTNK2TTKKCNH2 | |
| SCHEMBL9609441 | 0.84 | TTK (0.52) | EGFRTNK2TTK | |
| SCHEMBL215533 | 0.84 | TNK2 (0.48) | EGFRTNK2TTK | |
| SCHEMBL8512769 | 0.83 | EGFR (0.40) | EGFRTNK2TTKKCNH2 | |
| SCHEMBL8510506 | 0.83 | TNK2 (0.48) | EGFRTNK2TTK | |
| SCHEMBL8513510 | 0.83 | FLT3 (0.48) | TTKCDK4CCND1CCND3 | |
| SCHEMBL8513556 | 0.82 | TNK2 (0.46) | EGFRTNK2TTK | |
| SCHEMBL8508710 | 0.81 | WEE1 (0.50) | EGFRTNK2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288396-B2 | Pyrimidopyrimidoindazole derivative | MSDKK (JP) | 2012-10-16 | — | — | US | disclosed |
| US-8288396-B2 | Pyrimidopyrimidoindazole derivative | MSDKK (JP) | 2012-10-16 | — | — | US | disclosed |
| US-20120134955-A1 | PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE | MSD K.K. (JP) | 2012-05-31 | — | — | US | disclosed |
| US-20120134955-A1 | PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE | MSD K.K. (JP) | 2012-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120134955-A1 | PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE | WEE1, WEE2, DCK | EGFR 425/4885TNK2 170/4885TTK 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.